8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Mar 4, 2026·SEC
TScan Therapeutics, Inc.(TCRX)Earnings, Financials & Key Ratios
TCRX•NASDAQ
$1.25
$162M mkt cap·Price updated May 6, 2026
AboutTScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$10M+266.7%
- EBITDA-$133M-1.7%
- Net Income-$130M-1.8%
- EPS (Diluted)-1.00+12.3%
- Gross Margin72.24%-27.8%
- EBITDA Margin-1287.62%+72.3%
- Operating Margin-1315.38%+72.5%
- Net Margin-1256.81%+72.2%
- ROE-71.28%-9.5%
- ROIC-90.74%-21.0%
- Debt/Equity0.76+89.2%
- Interest Coverage-49.05-44.7%
TCRX Key Insights
TScan Therapeutics, Inc. (TCRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 56.9%
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Profits declining 37.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 16.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TCRX Price & Volume
TScan Therapeutics, Inc. (TCRX) stock price & volume — 10-year historical chart
Loading chart...
TCRX Growth Metrics
TScan Therapeutics, Inc. (TCRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years56.92%
3 Years-8.63%
TTM84.44%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5.46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM11.93%
Return on Capital
10 Years-46.3%
5 Years-45.54%
3 Years-46.86%
Last Year-49.82%
TCRX Recent Earnings
TScan Therapeutics, Inc. (TCRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 6, 2026EPS
$0.22
Est $0.20
-8.6%
Revenue
$982,000
Est $3M
-60.7%
Q2 2026
Mar 4, 2026EPS
$0.18
Est $0.27
+33.3%
Revenue
$3M
Est $2M
+5.4%
Q4 2025
Nov 12, 2025EPS
$0.28
Est $0.35
+20.0%
Revenue
$3M
Est $2M
+29.4%
Q3 2025
Aug 12, 2025EPS
$0.28
Est $0.28
+0.0%
Revenue
$3M
Est $2M
+65.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.22vs $0.20-8.6% | $982,000vs $3M-60.7% |
| Q2 2026 | Mar 4, 2026 | $0.18vs $0.27+33.3% | $3Mvs $2M+5.4% |
| Q4 2025 | Nov 12, 2025 | $0.28vs $0.35+20.0% | $3Mvs $2M+29.4% |
| Q3 2025 | Aug 12, 2025 | $0.28vs $0.28+0.0% | $3Mvs $2M+65.4% |
Based on last 12 quarters of dataView full earnings history →
TCRX Peer Comparison
TScan Therapeutics, Inc. (TCRX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 TCRT | 5.74M | 2.63 | -0.90 | 100% | -670.83% | -167.97% | ||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 CABA | 381.44M | 3.73 | -2.27 | -121.73% | 0.24 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 |
Compare TCRX vs Peers
TScan Therapeutics, Inc. (TCRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TCRX Income Statement
TScan Therapeutics, Inc. (TCRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 1.08M | 10.14M | 13.54M | 21.05M | 2.82M | 10.32M | 8.15M |
| Revenue Growth % | - | - | 834.65% | 33.47% | 55.52% | -86.62% | 266.65% | 84.44% |
| Cost of Goods Sold | 9.44M | 20.58M | 0 | 0 | 0 | 0 | 2.87M | 1.49M |
| COGS % of Revenue | - | 1896.5% | - | - | - | - | 27.76% | - |
| Gross Profit | -9.44M▲ 0% | -19.49M▼ 106.4% | 10.14M▲ 152.0% | 13.54M▲ 33.5% | 21.05M▲ 55.5% | 2.82M▼ 86.6% | 7.46M▲ 164.9% | 6.66M▲ 0% |
| Gross Margin % | - | -1796.5% | 100% | 100% | 100% | 100% | 72.24% | 81.73% |
| Gross Profit Growth % | - | -106.44% | 152.03% | 33.47% | 55.52% | -86.62% | 164.88% | - |
| Operating Expenses | 4.77M | 6.74M | 58.78M | 80.17M | 114.51M | 137.64M | 143.27M | 136.35M |
| OpEx % of Revenue | - | 621.29% | 579.65% | 592.32% | 544% | 4887.68% | 1387.62% | - |
| Selling, General & Admin | 4.77M | 6.74M | 13.83M | 20.35M | 25.49M | 29.56M | 31.99M | 31.22M |
| SG&A % of Revenue | - | 621.29% | 136.36% | 150.37% | 121.11% | 1049.68% | 309.81% | - |
| Research & Development | 9.44M | 20.58M | 44.95M | 59.82M | 88.15M | 107.35M | 114.15M | 105.67M |
| R&D % of Revenue | - | 1896.5% | 443.29% | 441.96% | 418.8% | 3812.14% | 1105.57% | - |
| Other Operating Expenses | -9.44M | -20.58M | 0 | 0 | 862K | 728K | -2.87M | -547K |
| Operating Income | -14.21M▲ 0% | -26.23M▼ 84.6% | -48.64M▼ 85.4% | -66.64M▼ 37.0% | -93.46M▼ 40.3% | -134.82M▼ 44.3% | -135.81M▼ 0.7% | -128.7M▲ 0% |
| Operating Margin % | - | -2417.79% | -479.65% | -492.32% | -444% | -4787.68% | -1315.38% | -1578.39% |
| Operating Income Growth % | - | -84.61% | -85.42% | -37% | -40.25% | -44.26% | -0.74% | - |
| EBITDA | -13.69M | -25M | -45.31M | -61.5M | -88.1M | -130.71M | -132.95M | -126.51M |
| EBITDA Margin % | - | -2304.42% | -446.83% | -454.37% | -418.53% | -4641.8% | -1287.62% | -1551.56% |
| EBITDA Growth % | - | -82.62% | -81.23% | -35.72% | -43.25% | -48.37% | -1.71% | 7.09% |
| D&A (Non-Cash Add-back) | 519K | 1.23M | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M | 2.19M |
| EBIT | -14.21M | -26.23M | -48.63M | -65.05M | -85.46M | -123.85M | -135.81M | -102.36M |
| Net Interest Income | 552K | 106K | 16K | 415K | 4.24M | 8.41M | 6.05M | 1.88M |
| Interest Income | 552K | 106K | 16K | 1.59M | 8M | 12.06M | 8.82M | 3.97M |
| Interest Expense | 0 | 0 | 0 | 1.18M | 3.76M | 3.65M | 2.77M | 1.4M |
| Other Income/Expense | 552K | 106K | 16K | 415K | 4.24M | 7.32M | 6.05M | 4.4M |
| Pretax Income | -13.66M▲ 0% | -26.13M▼ 91.3% | -48.63M▼ 86.1% | -66.22M▼ 36.2% | -89.22M▼ 34.7% | -127.5M▼ 42.9% | -129.77M▼ 1.8% | -124.31M▲ 0% |
| Pretax Margin % | - | -2408.02% | -479.49% | -489.26% | -423.86% | -4527.66% | -1256.81% | -1524.47% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -13.66M▲ 0% | -26.13M▼ 91.3% | -48.63M▼ 86.1% | -66.22M▼ 36.2% | -89.22M▼ 34.7% | -127.5M▼ 42.9% | -129.77M▼ 1.8% | -124.31M▲ 0% |
| Net Margin % | - | -2408.02% | -479.49% | -489.26% | -423.86% | -4527.66% | -1256.81% | -1524.47% |
| Net Income Growth % | - | -91.29% | -86.11% | -36.19% | -34.73% | -42.91% | -1.78% | 5.46% |
| Net Income (Continuing) | -13.66M | -26.13M | -48.63M | -66.22M | -89.22M | -127.5M | -129.77M | -124.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.53▲ 0% | -1.04▼ 96.2% | -2.03▼ 95.2% | -2.74▼ 35.0% | -1.36▲ 50.4% | -1.14▲ 16.2% | -1.00▲ 12.3% | -0.96▲ 0% |
| EPS Growth % | - | -96.23% | -95.19% | -34.98% | 50.37% | 16.18% | 12.28% | 11.93% |
| EPS (Basic) | -0.53 | -1.04 | -2.03 | -2.74 | -1.36 | -1.14 | -1.00 | - |
| Diluted Shares Outstanding | 24.94M | 24.94M | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M | 129.91M |
| Basic Shares Outstanding | 24.94M | 24.94M | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M | 129.91M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
TCRX Balance Sheet
TScan Therapeutics, Inc. (TCRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 42.38M | 36.45M | 165.65M | 124.13M | 194.24M | 292.72M | 152.41M | 132.77M |
| Cash & Short-Term Investments | 41.76M | 34.79M | 161.41M | 120.03M | 192.04M | 290.11M | 152.41M | 128.06M |
| Cash Only | 41.76M | 34.79M | 161.41M | 120.03M | 133.36M | 178.69M | 152.41M | 128.06M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 58.69M | 111.42M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 4.25M | 4.1M | 2.19M | 2.61M | 0 | 4.71M |
| Total Non-Current Assets | 7M | 13.29M | 22.45M | 74.96M | 77.91M | 78.4M | 76.38M | 69.22M |
| Property, Plant & Equipment | 6.41M | 12.53M | 17.26M | 69.2M | 71.23M | 71.6M | 0 | 64.13M |
| Fixed Asset Turnover | - | 0.09x | 0.59x | 0.20x | 0.30x | 0.04x | - | 0.16x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 5.2M | 5.04M | 0 | 0 | 5.03M | 10.06M |
| Other Non-Current Assets | 595K | 761K | 0 | 725K | 6.68M | 6.8M | 71.35M | 83.55M |
| Total Assets | 49.38M▲ 0% | 49.74M▲ 0.7% | 188.11M▲ 278.2% | 199.09M▲ 5.8% | 272.15M▲ 36.7% | 371.12M▲ 36.4% | 228.79M▼ 38.4% | 201.99M▲ 0% |
| Asset Turnover | - | 0.02x | 0.05x | 0.07x | 0.08x | 0.01x | 0.05x | 0.03x |
| Asset Growth % | - | 0.72% | 278.2% | 5.84% | 36.7% | 36.37% | -38.35% | -122.65% |
| Total Current Liabilities | 2.4M | 17.45M | 21.34M | 17.3M | 29.82M | 35.96M | 18.7M | 19.97M |
| Accounts Payable | 1.01M | 2.91M | 1.76M | 2.91M | 2.37M | 4.28M | 1.24M | 2.3M |
| Days Payables Outstanding | 39.04 | 51.62 | - | - | - | - | 158.05 | 884.08 |
| Short-Term Debt | 0 | 0 | 1.65M | 3.68M | 3.35M | 0 | 7.17M | 7.44M |
| Deferred Revenue (Current) | 0 | 10.63M | 11.41M | 3.87M | 10.14M | 11.7M | 0 | 14.52M |
| Other Current Liabilities | 31K | 1.67M | 3.92M | 2.48M | 5.9M | 6.92M | 10.29M | 10.89M |
| Current Ratio | 17.69x | 2.09x | 7.76x | 7.17x | 6.51x | 8.14x | 8.15x | 8.15x |
| Quick Ratio | 17.69x | 2.09x | 7.76x | 7.17x | 6.51x | 8.14x | 8.15x | 8.15x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 4.44M | 74.75M | 5.99M | 82.35M | 91.46M | 94.19M | 86.97M | 85.1M |
| Long-Term Debt | 0 | 0 | 0 | 29.29M | 26.7M | 32.07M | 32.53M | 52.45M |
| Capital Lease Obligations | 4.44M | 6.02M | 4.39M | 53.01M | 59.14M | 60.74M | 54.44M | 168.86M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 59.92M | 97K | 49K | 0 | 135K | 0 | 33.05M |
| Total Liabilities | 6.84M | 92.2M | 27.33M | 99.66M | 121.28M | 130.15M | 105.67M | 105.07M |
| Total Debt | 4.89M | 7.43M | 6.04M | 85.98M | 92.43M | 97.38M | 94.14M | 59.88M |
| Net Debt | -36.88M | -27.36M | -155.36M | -34.04M | -40.93M | -81.31M | -58.27M | -68.17M |
| Debt / Equity | 0.11x | - | 0.04x | 0.86x | 0.61x | 0.40x | 0.76x | 0.76x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.47x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.54x |
| Interest Coverage | - | - | - | -55.31x | -22.73x | -33.90x | -49.05x | -73.07x |
| Total Equity | 42.54M▲ 0% | -42.46M▼ 199.8% | 160.78M▲ 478.6% | 99.43M▼ 38.2% | 150.87M▲ 51.7% | 240.97M▲ 59.7% | 123.12M▼ 48.9% | 96.92M▲ 0% |
| Equity Growth % | - | -199.81% | 478.64% | -38.15% | 51.73% | 59.72% | -48.91% | -170.69% |
| Book Value per Share | 1.71 | -1.70 | 6.72 | 4.13 | 2.30 | 2.15 | 0.95 | 0.75 |
| Total Shareholders' Equity | 42.54M | -42.46M | 160.78M | 99.43M | 150.87M | 240.97M | 123.12M | 96.92M |
| Common Stock | 0 | 1K | 3K | 3K | 5K | 6K | 5K | 6K |
| Retained Earnings | -17.41M | -43.53M | -92.16M | -158.38M | -247.6M | -375.1M | -504.86M | -533.53M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 51K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TCRX Cash Flow Statement
TScan Therapeutics, Inc. (TCRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.52M | -3.02M | -48.68M | -66.5M | -61.36M | -110.82M | -135.32M | -135.32M |
| Operating CF Margin % | - | -278.62% | -480% | -491.34% | -291.5% | -3935.44% | -1310.6% | - |
| Operating CF Growth % | - | 75.86% | -1510.22% | -36.62% | 7.74% | -80.62% | -22.1% | -24.48% |
| Net Income | -13.66M | -26.13M | -48.63M | -66.22M | -89.22M | -127.5M | -129.77M | -124.31M |
| Depreciation & Amortization | 519K | 1.23M | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M | 2.88M |
| Stock-Based Compensation | 240K | 515K | 2.52M | 4.55M | 5.21M | 9.55M | 11.71M | 10.76M |
| Deferred Taxes | 0 | 0 | -9.16M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 78K | 2K | 9.16M | 260K | -315K | -2.03M | -1.95M | 449K |
| Working Capital Changes | 299K | 21.36M | -5.9M | -10.23M | 17.61M | 5.05M | -18.18M | -11.79M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 161K | 1.13M | 10K | 528K | -52K | 1.99M | -3.01M | -2.52M |
| Cash from Investing | -1.25M | -4.24M | -9.94M | -4.22M | -60.76M | -52.61M | 109.37M | 95.77M |
| Capital Expenditures | -1.25M | -4.24M | -9.94M | -4.22M | -3.15M | -3.83M | -4.41M | -2.94M |
| CapEx % of Revenue | - | 390.6% | 98.03% | 31.22% | 14.95% | 135.83% | 42.68% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 34.81M | 288K | 189.67M | 29.36M | 135.44M | 208.76M | -336K | 189K |
| Debt Issued (Net) | 0 | 0 | 0 | 29.35M | 0 | 15.31M | 0 | 0 |
| Equity Issued (Net) | 34.81M | 288K | 189.38M | 193K | 42.41M | 33.13M | 264K | 264K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 191K |
| Other Financing | 5K | 0 | 291K | -191K | 93.03M | 160.32M | -600K | -75K |
| Net Change in Cash | 21.04M▲ 0% | -6.97M▼ 133.1% | 131.05M▲ 1979.4% | -41.37M▼ 131.6% | 13.33M▲ 132.2% | 45.33M▲ 240.2% | -26.28M▼ 158.0% | -26.05M▲ 0% |
| Free Cash Flow | -13.77M▲ 0% | -7.26M▲ 47.3% | -58.62M▼ 707.3% | -70.73M▼ 20.7% | -64.5M▲ 8.8% | -114.65M▼ 77.7% | -139.73M▼ 21.9% | -124.96M▲ 0% |
| FCF Margin % | - | -669.22% | -578.03% | -522.56% | -306.45% | -4071.27% | -1353.28% | -1532.46% |
| FCF Growth % | - | 47.27% | -707.3% | -20.66% | 8.8% | -77.74% | -21.88% | -0.94% |
| FCF per Share | -0.55 | -0.29 | -2.45 | -2.94 | -0.98 | -1.02 | -1.08 | -1.08 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.12x | 1.00x | 1.00x | 0.69x | 0.87x | 1.04x | 1.01x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TCRX Key Ratios
TScan Therapeutics, Inc. (TCRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -64511.11% | -82.2% | -50.9% | -71.29% | -65.08% | -71.28% | -91.94% |
| Return on Invested Capital (ROIC) | - | - | -141.16% | -79.96% | -75.01% | -90.74% | -90.74% |
| Gross Margin | -1796.5% | 100% | 100% | 100% | 100% | 72.24% | 81.73% |
| Net Margin | -2408.02% | -479.49% | -489.26% | -423.86% | -4527.66% | -1256.81% | -1524.47% |
| Debt / Equity | - | 0.04x | 0.86x | 0.61x | 0.40x | 0.76x | 0.76x |
| Interest Coverage | - | - | -55.31x | -22.73x | -33.90x | -49.05x | -73.07x |
| FCF Conversion | 0.12x | 1.00x | 1.00x | 0.69x | 0.87x | 1.04x | 1.01x |
| Revenue Growth | - | 834.65% | 33.47% | 55.52% | -86.62% | 266.65% | 84.44% |
TCRX SEC Filings & Documents
TScan Therapeutics, Inc. (TCRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TCRX Frequently Asked Questions
TScan Therapeutics, Inc. (TCRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TScan Therapeutics, Inc. (TCRX) reported $8.2M in revenue for fiscal year 2025.
TScan Therapeutics, Inc. (TCRX) grew revenue by 266.7% over the past year. This is strong growth.
TScan Therapeutics, Inc. (TCRX) reported a net loss of $124.3M for fiscal year 2025.
Dividend & Returns
TScan Therapeutics, Inc. (TCRX) has a return on equity (ROE) of -71.3%. Negative ROE indicates the company is unprofitable.
TScan Therapeutics, Inc. (TCRX) had negative free cash flow of $125.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More TCRX
TScan Therapeutics, Inc. (TCRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates